



Contact: Robert Yokel, Ph.D.

Location: Lexington, KY

Email: Robert.Yokel@ALKYMOS.com

Tel: 859-257-4855

Website: WWW.alkymos.com



## Company Profile

**Industry Sector:** Medical/ Pharmaceutical

**Company Overview:** Alkymos designs, synthesizes, and produces chelators and chelator based technology for use in clinical and laboratory settings.

**Target Market(s):** Initially: Neonatal Intensive Care Units.

## Key Value Drivers

**Technology\*:** Toxic metal removal from solutions using immobilized tethered chelators.

**Competitive Advantage:** Two issued U.S. Patents. One U.S. Patent Pending. One Canadian Patent pending.

Only proven solution to remove up to 90% of aluminum from Ca gluconate used in the preparation of total parenteral nutrition solutions for neonates.

**Plan & Strategy:** Initially a “go it alone” product launch. May partner with an established firm in the sector if conditions warrant.

\*Technology funded by the NIH and Commonwealth of Kentucky and being commercialized with assistance from the NIH-CAP program.

## Management

### Leadership:

Robert Yokel, Ph.D., President  
Gordon Garrett, MBA, V.P. Business Management  
Wes Harris, Ph.D., Secretary and Treasurer

### Scientific Advisory Board:

## Product Pipeline

A filter to remove aluminum from Ca gluconate:

	Q2 2013	Q 3 2013	Q4 2013	Q1 2014
Alpha Units	X			
Beta Units		X		
Initial Release			X	
Full Launch				X

